Hutchmed announces BTD in China for Orpathys, Tagrisso combination

Hutchmed (HCM) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA, has granted breakthrough therapy designation, or BTD, to the combination of Orpathys and Tagrisso for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on EGFR inhibitor therapy. Orpathys is an oral, potent and highly selective MET tyrosine kinase inhibitor.